Bausch + Lomb (NYSE: BLCO) appoints Eduardo Alfonso and Steven Collis to board

Rhea-AI Filing Summary

Bausch + Lomb Corporation announced that it has appointed Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026. They are filling vacancies created by the departures of Brett Icahn and Gary Hu from the board in August 2025.

The board determined that both new directors are independent under New York Stock Exchange and Toronto Stock Exchange rules and the company’s corporate governance guidelines. They have not yet been appointed to any board committees, will receive compensation under the standard Non-Employee Directors Compensation Policy, and have entered into the company’s standard director indemnification agreements. The company states there are no special arrangements or related-party transactions involving either new director that require disclosure.

Bausch & Lomb Corp NYSE false 0001860742 0001860742 2025-12-17 2025-12-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

December 17, 2025

Date of Report (Date of the earliest event reported)

Bausch + Lomb Corporation

(Exact Name of Registrant as Specified in Its Charter)

Canada		001-41380		98-1613662
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File Number)		(I.R.S. Employer Identification Number)

520 Applewood Crescent

Vaughan, Ontario

Canada L4K 4B4

(Address of Principal Executive Offices) (Zip Code)

(905) 695-7700

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, No Par Value		BLCO		New York Stock Exchange		Toronto Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 17, 2025, Bausch + Lomb Corporation (the “Company”) announced the appointment of Eduardo C. Alfonso, MD and Steven H. Collis to its board of directors (the “Board”), effective January 1, 2026, to fill the vacancies created by the departure of Brett Icahn and Gary Hu from the Board in August 2025. The Board has determined that each of Dr. Alfonso and Mr. Collis is independent in accordance with applicable New York Stock Exchange and Toronto Stock Exchange rules and the Company’s corporate governance guidelines. Dr. Alfonso and Mr. Collis have not been appointed to serve on any committees of the Board.

Dr. Alfonso and Mr. Collis will receive compensation in accordance with the Company’s Non-Employee Directors Compensation Policy (as in effect from time to time) and have entered into the Company’s standard form of director indemnification agreement.

There are no arrangements or understandings between any of Dr. Alfonso and Mr. Collis and any other person pursuant to which any of Dr. Alfonso and Mr. Collis was selected as a director, and there are no transactions in which the Company is a party and in which any of Dr. Alfonso and Mr. Collis has a material interest subject to disclosure under Item 404(a) of Regulation S-K.

A copy of the press release announcing the appointments is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release, dated December 17, 2025.
104		Cover Page Interactive Data File (formatted as Inline XBRL).

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BAUSCH + LOMB CORPORATION
By:		/s/ A. Robert D. Bailey
Name:		A. Robert D. Bailey
Title:		Executive Vice President and Chief Legal Officer

Date: December 17, 2025

FAQ

What board changes did Bausch + Lomb (BLCO) disclose on December 17, 2025?

Bausch + Lomb Corporation announced the appointment of Eduardo C. Alfonso, MD, and Steven H. Collis to its board of directors, effective January 1, 2026, to fill vacancies created by the departures of Brett Icahn and Gary Hu in August 2025.

Are the new Bausch + Lomb (BLCO) directors considered independent?

The board determined that both Dr. Alfonso and Mr. Collis are independent in accordance with applicable New York Stock Exchange and Toronto Stock Exchange rules and the company’s corporate governance guidelines.

Will the new Bausch + Lomb (BLCO) directors serve on any board committees?

As of this announcement, Dr. Alfonso and Mr. Collis have not been appointed to serve on any committees of the board of directors.

How will Bausch + Lomb (BLCO) compensate its new non-employee directors?

Dr. Alfonso and Mr. Collis will receive compensation under the company’s Non-Employee Directors Compensation Policy, as in effect from time to time, and each has entered into the company’s standard form of director indemnification agreement.

Are there any special arrangements related to the selection of the new Bausch + Lomb (BLCO) directors?

The company states there are no arrangements or understandings between either Dr. Alfonso or Mr. Collis and any other person pursuant to which they were selected as directors.

Do the new Bausch + Lomb (BLCO) directors have any related-party transactions with the company?

The company reports that there are no transactions in which it is a party and in which either Dr. Alfonso or Mr. Collis has a material interest that would require disclosure under Item 404(a) of Regulation S-K.

Did Bausch + Lomb (BLCO) issue a press release about the new director appointments?

Yes. A press release dated December 17, 2025 announcing the appointments of Dr. Alfonso and Mr. Collis is included as Exhibit 99.1.